Impact of Ruxolitinib Cream on Work Productivity and Activity Impairment and Associated Indirect Costs in Patients with Atopic Dermatitis: Pooled Results From Two Phase III Studies.

Am J Clin Dermatol · 2023 · PMC9870821 · PMID 36264430

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Significant differences at week 8 were noted for absenteeism with 0.75% ruxolitinib cream versus vehicle (1.3% vs 7.4%; p < 0.05), and 1.5% ruxolitinib cream (4.8%) showed a trend toward difference versus vehicle.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.